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Abstract Mechanisms of muscle atrophy are complex and their understanding might help
finding therapeutic solutions for pathologies such as amyotrophic lateral sclerosis (ALS). We meta-
analyzed transcriptomic experiments of muscles of ALS patients and mouse models, uncovering a
p53 deregulation as common denominator. We then characterized the induction of several p53
family members (p53, p63, p73) and a correlation between the levels of p53 family target genes
and the severity of muscle atrophy in ALS patients and mice. In particular, we observed increased
p63 protein levels in the fibers of atrophic muscles via denervation-dependent and -independent
mechanisms. At a functional level, we demonstrated that TAp63 and p53 transactivate the
promoter and increased the expression of Trim63 (MuRF1), an effector of muscle atrophy.
Altogether, these results suggest a novel function for p63 as a contributor to muscular atrophic
processes via the regulation of multiple genes, including the muscle atrophy gene Trim63.
DOI: 10.7554/eLife.10528.001
Introduction
Muscle atrophy is associated with aging, cancer, AIDS and neurodegenerative diseases such as
amyotrophic lateral sclerosis (ALS) (von Haehling et al., 2010). Although muscle atrophy is not nec-
essarily the primary target of the pathology, it is often an important cause of lethality. For example,
atrophy and dysfunction of respiratory muscles lead to death in ALS patients (Rothstein, 2009). As
muscle atrophy is associated with complex pathologies, the exact mechanisms inducing muscle atro-
phy are varied and still debated. Typically, ALS has been considered a neurodegenerative pathology
specifically causing alteration in motor neurons, but more recent findings indicate that the etiology
of the pathology is more complex. Indeed, a number of additional cell types, such as astrocytes
(Yamanaka et al., 2008), microglia (Boille´e et al., 2006) and muscle cells (Wong and Martin,
2010), have been described to be directly affected by the pathology and therefore to participate in
the muscle atrophy.
Around 20% of all inherited ALS cases can be linked to mutations in the gene encoding SOD1.
Cellular events (Pansarasa et al., 2014) that have been shown to be triggered by these different
mutations include aggregation of SOD1 proteins in the cytoplasm (Hart, 2006), increase in oxidative
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stress (Barber and Shaw, 2010) and subsequent DNA damage (Aguirre et al., 2005), endoplasmic
reticulum (ER) stress (Nishitoh et al., 2008) or alterations of mitochondrial function (Manfredi and
Xu, 2005). In addition, novel mutated genes (FUS, TARDBP. . .) have been linked to ALS with differ-
ences in the pathophysiological outcomes (Chen et al., 2013). These differences might be linked to
the different impacts of the mutated proteins at the molecular level. Indeed, protein aggregates or
other alterations induced by SOD1 mutants have been characterized in muscle cells, while other
mutated proteins linked to ALS seem to not directly affect muscles (Pansarasa et al., 2014).
To date, the exact molecular mechanisms driving muscle catabolism in the symptomatic phase of
ALS remain poorly understood. It is also only during the symptomatic phase that ALS pathology can
be diagnosed. The absence of pre-symptomatic markers highlights the need for understanding the
muscle catabolic processes for therapeutic purposes. Several observations indicate that the p53 fam-
ily members (p53, p63, p73) play an important role in muscle physiopathology and might therefore
represent actors of the muscle atrophy (Schwarzkopf et al., 2006; Mazzaro et al., 1999;
Cam et al., 2006; Fontemaggi et al., 2001; Martin et al., 2011; Rouleau et al., 2011;
Belloni et al., 2006; Su et al., 2012).
The p53 family of transcription factors is a central regulator of cellular processes such as apopto-
sis, cell cycle arrest, metabolism or cellular differentiation through the regulation of several target
genes (CDKN1A, BAX, GADD45A, MDM2 and others) (Arrowsmith, 1999; Menendez et al., 2009).
All three members encode TA and 4N isoforms that vary in their N-terminus due to alternate pro-
moter usage where TA has a canonical transactivation domain. DN isoforms lack such a domain and
can serve as dominant negatives versus the TA isoforms in some cases, although they are also capa-
ble of transactivating certain genes (De Laurenzi et al., 1998; Casciano et al., 1999; Murray-
Zmijewski et al., 2006).
Through their cellular activities, p53 proteins are involved in a broad variety of physiological func-
tions that include tumor suppression and organ development (Arrowsmith, 1999). For example,
p53 plays a role in the response against tumor-inducing events such as DNA damage, oncogene
activation, and a variety of additional cellular stresses (hypoxia, reactive oxygen species (ROS), or
alteration of energy metabolism) (Marcel et al., 2011; Rufini et al., 2013; Gonfloni et al., 2014). In
addition, several studies have highlighted the involvement of the p53 family members in neurode-
generative diseases. p53 as well as p63 and p73 have been shown to regulate neuronal apoptosis
and their activation has been observed in various neurodegenerative diseases, such as Alzheimer,
Parkinson and Angelman syndromes (Jiang et al., 1998; de la Monte et al., 1997; Seidl et al.,
1999; Bui et al., 2009; Benosman et al., 2007; Benosman et al., 2011). We have previously
eLife digest Many conditions, including cancer and AIDS, lead to a person’s muscles wasting
away. Often the muscles are not necessarily the prime targets of these diseases. However, in the
case of a neurodegenerative disease called amyotrophic laterals sclerosis (or ALS), it is the muscle
degeneration that ultimately leads to the death of patients within a few years. There is currently no
treatment for ALS. This is partly because the mechanisms behind the disease are poorly understood.
However, proteins belonging to the so-called p53 family have been implicated as possibly being
involved in the degenerative processes in muscles.
The p53 family comprises three proteins called p53, p63 and p73. These proteins bind to DNA to
switch genes on or off, and target genes involved in a range of cellular processes such as DNA
repair and cell death. von Grabowiecki et al. have now identified p63 as a protein that contributes to
muscle wasting in ALS. The production of p63 in degenerated muscles increases as the disease
progresses, both in patients and in a mouse model of the condition. Further analysis then showed
that the protein p63 regulates an enzyme that actually breaks down the building blocks of muscles,
which directly leads to the muscle wasting.
Following on from this work, the next step is to verify if the p53 family are also involved in muscle
wasting that arises from other diseases. This will enable researchers to look for similarities that could
highlight new opportunities to treat conditions that cause muscle wasting.
DOI: 10.7554/eLife.10528.002
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reported an induction of p53 in degenerating spinal cord motor neurons in an ALS mouse model
expressing mutated Cu/Zn superoxide dismutase 1 (SOD1[G86R]) (Gonza´lez de Aguilar et al.,
2000).
In muscles, p53 is activated during myogenic differentiation, participates with MyoD to induce
myogenesis, and mediates doxorubicin-induced muscle atrophy via its target gene pw1
(Schwarzkopf et al., 2006; Mazzaro et al., 1999). Nonetheless, p53 expression is not essential for
muscle development (Donehower et al., 1992) or regeneration (White et al., 2002), which could be
explained by compensatory mechanisms involving p63 and p73. Indeed, more recent studies have
shown that p63 and p73 are also involved in myoblast differentiation (Cam et al., 2006;
Fontemaggi et al., 2001; Martin et al., 2011; Rouleau et al., 2011) and DNp73 appears to protect
muscle cells against stresses (Belloni et al., 2006). Finally, a study showed that p63 is important for
the regulation of muscle cell metabolism via the regulation of Sirtuins and AMPK (Su et al., 2012).
In this study, we investigated the regulation and the role of the transcription factors of the p53
family in muscular atrophy during ALS based on a meta-analysis we performed with 4 microarray
experiments obtained with biopsies of muscles from ALS patients or with muscles from ALS mouse
models.
Results
p53-target genes and p53 regulators are induced in atrophic muscles
during ALS
To identify the molecular mechanisms involved in muscle atrophy during ALS we performed a meta-
analysis using four independent microarray experiments deposited at the Array Express database
(EMBL-EBI). Two experiments contained gene expression data for the muscle of ALS patients and
control individuals (E-MEXP-3260; E-GEOD-41414, [Pradat et al., 2012; Bernardini et al., 2013]).
One experiment contained gene expression data for muscles of SOD1(G86R) mice that represents
an ALS model in which the onset of the pathology is at 105 days of age (E-TABM-195 [Gonzalez de
Aguilar et al., 2008]). The last experiment contained gene expression data for muscles of SOD1
(G93A) mice in which onset of the pathology occurs at 14 weeks of age (E-GEOD-16361,
[Capitanio et al., 2012]). Beside the better pathophysiological relevance, data obtained from biop-
sies of ALS patients also provided a better representation of the diversity of the genetic anomalies
observed in patients. In addition, patients were at various stage of the pathology, hence establishing
a representative scale of muscle alterations. The panel of datasets we chose also included two differ-
ent mouse models of ALS, allowing us to pinpoint common and specific deregulations. Importantly,
the SOD1 mouse models are well characterized for their muscular phenotype alterations. In particu-
lar, it has already been established that SOD1 mutants present altered functions in muscles, in con-
trast to other mutated proteins linked to ALS (TARDBP, FUS etc) (Pansarasa et al., 2014).
After standard normalization and statistical analyses, each experiment was independently sub-
jected to gene ontology, signaling pathway, transcription factor, and miRNA analyses. Fold induction
between control individuals and ALS individuals was set to twofold change and rawp value inferior
to 0.05. We decided to focus on transcription factor deregulations. The bioinformatic analyses we
performed pinpointed to only 7 transcription factors whose activity, indicated by coherent changes
in expression of their target genes, was potentially deregulated in at least two out of four experi-
ments (Figure 1A). The activity of one transcription factor, NfKB, appeared deregulated only in
experiments done with the mouse models. Deregulation of STAT1 activity was identified in three
experiments. Interestingly, the activity of only three transcription factors, MyoD, Myogenin and p53,
was identified to be commonly deregulated in all four experiments that included biopsies from
patients and animal models. MyoD and Myogenin are muscle specific transcription factors involved
in muscle cell differentiation (Zanou and Gailly, 2013). P53 was the transcription factor with the
highest number of deregulated genes (51 genes). Notably the p53 target genes CDKN1A,
GADD45A and PMAIP1, among others, were found induced in all four experiments.
As one of the experiments using biopsies of ALS patients included a scale (von Haehling et al.,
2010; Rothstein, 2009; Yamanaka et al., 2008; Boille´e et al., 2006; Wong and Martin, 2010;
Pansarasa et al., 2014) of muscle alteration, we analyzed whether the expression of some of these
genes might correlate with the severity of the pathology. We found that CDKNA1, GADD45A and
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PMAIP1 expression correlated with the degree of the pathology of the muscle from ALS patients
(Figure 1B).
Besides the bioinformatic analysis on the deregulation of transcription factors, the signaling path-
way analyses also indicated alterations in the p53 pathway characterized by deregulations in
upstream regulators of p53, such as MDM2 and thioredoxin, and a p53 family member, P63 (Table 1,
Figure 1B, Figure 1—figure supplement 1). In particular, the expression of P63 correlated with the
severity of the pathology in muscles biopsies from ALS patients (Figure 1B).
In order to validate the bioinformatic analyses we performed RT-qPCR experiments with RNA
from muscle biopsies of an independent group of ALS patients. We confirmed that CDKN1A,
GADD45A and PMAIP1 were induced in the muscle biopsies of ALS patients (Figure 2A,B,C). Simi-
larly, we analyzed the expression of these genes using muscle samples of independent groups of
SOD1(G86R) mice. Groups analyzed at 60 days and 75 days of age correspond to the asymptomatic
stage, while 90 day-old groups correspond to an early or pre-symptomatic stage associated with
Figure 1. Microarray meta-analysis highlights links between the deregulation of p53 family related genes and ALS.
(A) Representation of the number of deregulated target genes of the indicated transcription factors. Data were
obtained using the indicated datasets from the Array Express database (EMBL-EBI) and quantification was carried
out from AltAnalyze software analyses on transcription factor databanks (complete data in Supplementary file 2A,
B,C,D. (B) mRNA levels from nine ALS patient deltoid muscles as by DNA microarray were correlated with the
intensity of muscle injury. Expression data were generated using a murine gene profiling database deposited at
ebi.ac.uk/arrayexpress (accession number E-MEXP-3260). In the corresponding study, muscle injury was estimated
according to a composite score combining manual testing of strength of shoulder abductors and the degree of
myofiber atrophy. This score ranges from 6 (normal strength and very low level of atrophy) to 1 (total paralysis and
high level of atrophy). Each point represents an individual. Correlation coefficients (r) and p-values were
determined by Spearman correlation test.
DOI: 10.7554/eLife.10528.003
The following figure supplements are available for figure 1:
Figure supplement 1. Regulation of p53-family related genes in skeletal muscle of SOD1(G86R) and denervated
mice.
DOI: 10.7554/eLife.10528.004
Figure supplement 2. mRNA levels from control and ALS patient deltoid muscles as by DNA microarray were
correlated with the intensity of muscle injury.
DOI: 10.7554/eLife.10528.005
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established gene deregulations (von Grabowiecki et al., 2015). Finally, the symptomatic stage
group (beginning after 105 days) is characterized by the onset of paralysis and marked muscle atro-
phy (Figure 2—figure supplement 1 Upregulation of the p53 target genes Gadd45a, Cdkn1a, Bax,
Pmaip1 and Perp was observed at 90 days and further increased at 105 days in SOD1(G86R) mice
(Figure 2D,E,F, Figure 2—figure supplement 2). In addition to these genes, we also analyzed by RT-
qPCR the expression of additional p53 target genes and regulators of p53 by RT-qPCR (Table 1). In
particular, the expression of p53 target genes involved in apoptosis (Pmaip1, Peg3 and Siva) was
also induced.
p53 proteins have recently been linked to energy metabolism and endoplasmic reticulum (ER)
stress pathway activation (Su et al., 2012; Ramadan et al., 2005; Zhu and Prives, 2009). Analysis of
the expression of p53 family target genes implicated in several metabolic pathways (Tigar, sestrins,
Sco2, Sirtuin1 or Prkaa1) (Su et al., 2012; Vousden and Ryan, 2009) or ER stress (Chop, Bip, or
Xbp1) (Stavridi and Halazonetis, 2004), did not reveal coherent regulation in respect to disease
progression (Table 1). For example, the expressions of Sesn2 and Tigar (Vousden and Ryan, 2009)
Table 1. Fold induction of p53-related genes in the ALS model SOD1 (G86R).
Gene name Function 90 d. 105 d.
p53-family target genes
Cdkn1a (p21) Cell cycle arrest 4 13
Gadd45a Cell cycle arrest 5,6 21
Peg3 Apoptosis inducing 3 7
Perp Cell cycle arrest 4 12
Pmaip1 Apoptosis effector 5 12
Bax Apoptosis effector 3 8
Siva Apoptosis inducing 3 5
Zmat3 Growth regulation 1,6 1,1
Eda2R NF.Kb/JNK pathway 3,4 9,4
Tigar Glucose metabolism 0,75 0,2
Sens1 ROS homeostasis - 16,3
Sens2 ROS homeostasis 1,27 1,46
Sco2 Glucose metabolism 1,18 0,91
Ddit3 (Chop) ER stress 1,14 0,35
Bip (Grp78) ER stress 1,25 1,08
Xbp1 ER stress 2 2,51
p53-family regulators
Mlf1 Cell cycle arrest/differentiation 0,9 0,2
Myf6 Differentiation 4 7
Mdm2 p53 degradation 4 6
Txn1 Oxidative stress response 4 6
Id2 Inhibition of differentiation 2 3,1
p53-family members
P53 4 3
TAp63 4 12
DNp63 0,5 0,3
TAp73 2 3
DNp73 0,9 0,8
Denervation/atrophy markers
Chrna1 (ACh Receptor alpha) Neuromuscular junction 4,2 12,4
DOI: 10.7554/eLife.10528.006
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Figure 2. p53-family target gene expression in muscles from ALS patients and in an ALS mouse model correlates
with disease intensity. (A–C) RNA from muscle biopsies of control and ALS patients (n = 8, Neuromuscular Unit
[BioBank of Skeletal Muscle, Nerve Tissue, DNA and cell lines]) was extracted and analyzed by RT-qPCR. Absolute
levels are normalized against the average of the control group. (D–F) p53 family target genes mRNA levels were
assayed in SOD1(G86R) mouse gastrocnemius muscle by RT-qPCR. Graphs are means of fold induction versus 60
days-old WT and of matching age (60, 75, 90, 105-days-old, n = 6) and experimental condition (wild-type, or SOD1
(G86R)). *p<0.01 compared to control, as calculated by a one-way ANOVA test followed by a Tukey post-test.
DOI: 10.7554/eLife.10528.007
The following figure supplement is available for figure 2:
Figure supplement 1. Gastrocnemius muscles from wild-type or symptomatic SOD1(G86R) (105 days) mice were
dissected and weighted.
DOI: 10.7554/eLife.10528.008
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were regulated in opposite directions during the progression of the disease. Therefore, our data
suggest that the correlation between ALS progression and p53 function might mostly be due to cell
growth arrest and cell death regulation.
We also confirmed by RT-qPCR an upregulation of several upstream regulators of the p53 family,
including Mdm2, Myf6, Mlf1, and Txn (Table 1) (Arrowsmith, 1999). Taken together, our results
suggest that a p53-like pathway is activated in ALS muscles both in patients and the murine SOD1
ALS-models.
p53-family members are regulated in mouse skeletal muscles during
ALS
As we observed in the muscle biopsies of ALS patients a correlation between p63 expression and
the severity of the pathology, we investigated the expression levels of p53 family members in the
muscles of SOD1(G86R) mice. Our analysis revealed an increased expression of TA isoforms of
Trp63 in SOD1(G86R) (Figure 3). Strikingly, the mRNA levels of TA isoforms of Trp63 were strongly
induced towards the end of the disease (105 day), while the mRNA levels for DN isoforms of Trp63
were downregulated during the same time period. A similar tendency was observed for p53, TA and
DN isoforms of p73, albeit at a lower magnitude. The expression of TA isoforms of Trp63 correlated
with acetylcholine receptor alpha (Chrna1) expression, a molecular marker indicating the severity of
muscular denervation. In addition, we analyzed the expression of two documented effectors of mus-
cular atrophy, namely Fbxo32 (Atrogin-1) and Trim63 (MuRF1). These proteins are E3 ubiquitin
ligases that target muscular proteins for degradation during muscular atrophy or remodeling
(Murton et al., 2008). Importantly, the deregulation of Trp63 expression also correlated with the
upregulation of these two markers. This is in accordance with our data from ALS patient muscle
biopsies, whereby the expression of P63 also correlated with the degree of muscle pathology
(Figure 1E).
p63 protein accumulates in muscle fibers during ALS
Based on the observed deregulation of P63 expression in ALS patients and the stronger upregula-
tion of TAp63 in SOD1(G86R) mice, we further analyzed p63 protein levels. Immunoblotting with a
TAp63 isoforms specific antibody revealed a striking accumulation of p63 proteins in muscles of
SOD1 (G86R) mice that correlated with the progression of the disease (Figure 4A). When probing
with a DNp63 specific antibody, however, we did not observe any specific band. The use of a p63
antibody directed against all p63 isoforms confirmed an upregulation of p63 in muscles of SOD1
(G86R) mice (Figure 4—figure supplement 1). Immunohistochemistry with the same antibody also
revealed markedly increased immunoreactivity in the nuclei of muscle fibers of SOD1(G86R)
(Figure 4B, Figure 4—figure supplement 3). In contrast, there was no significant increase in p73
staining (Figure 4—figure supplement 2). In this case, the apparent higher number of p73 positive
nuclei appeared to be due to the atrophy of the muscle fibers, increasing the density of cells/nuclei.
Similar experiments to detect expression of p53 did not yield a specific staining. However, we
observed by western blot some slight increase in p53 protein levels in protein extract of muscle from
SOD1(G86R) mice (Figure 4—figure supplement 1). Taken together, our data indicated a complex
regulation of p53 family members during muscular atrophy, highlighted by significant increase of
TAp63 messenger and protein expression levels in the skeletal muscles during ALS.
Muscle denervation induces a p63 response
We then further investigated the possible cause of the deregulation of Trp63 expression. Several
studies showed that the ALS etiology is complex and multifactorial, involving different cell types and
molecular mechanisms. One established cause of muscular atrophy is motor neuron degeneration
that leads to muscle denervation. However, it has also been shown that SOD1 mutants can also
directly cause alteration in muscle cells such as SOD1 protein aggregates and mitochondrial abnor-
malities (Pansarasa et al., 2014). To verify the first hypothesis, we induced denervation in 80 day-
old wild type and SOD1(G86R) mice by sciatic nerve crush, and gastrocnemius muscles were ana-
lyzed 7 days later. Our results showed that denervation upregulated TAp63 mRNA levels five-
to sixfold in wild-type mice (Figure 5A). Concomitantly, DNp63 levels were downregulated 0.4-fold
(Figure 5B). In SOD1(G86R) mice, nerve crush further accentuated changes in mRNA levels for TA
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and DN isoforms of Trp63. In addition, the TAp63 target genes Cdkn1a and Gadd45a were found
strongly induced after nerve crush (Figure 5C,D). These results show that nerve injury leading to
alteration of the motor axis seems to be sufficient to activate a TAp63 response.
Figure 3. Expression of p53-family members in SOD1(G86R) muscles. p53 family members, Chrna1 (Acetylcholine
receptor subunit alpha) or muscle atrophy effectors Trim63 (MuRF1) and Fbxo32 (Atrogin1) mRNA levels were
assayed in SOD1(G86R) mouse gastrocnemius muscle by RT-qPCR. Bars are means of fold induction versus ‘WT 60
days-old’ and of matching age (60, 75, 90, 105 days-old, n = 6) and experimental condition (WT or SOD1(G86R)).
*p<0.01 compared to control, as calculated by a one-way ANOVA test followed by a Tukey post-test.
DOI: 10.7554/eLife.10528.009
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Figure 4. p63 protein expression in SOD1(G86R) muscle. (A) Proteins from muscles were immuno-precipitated with a p63 antibody and then separated
on a 10% SDS PAGE gel. Western blot experiment was performed using an antibody against TAp63. Each experimental point is a pool of proteins from
6 animals. Graph represents quantification of the blot using ImageJ image analyzer software indicated a %/WT 60 day-old animals. (B) Gastrocnemius
muscles from wild-type or symptomatic SOD1(G86R) (105 days) mice were cryodissected and probed for total p63 protein.
DOI: 10.7554/eLife.10528.010
The following figure supplements are available for figure 4:
Figure supplement 1. p53 and p63 protein expression in muscles of SOD1(G86R) mice.
DOI: 10.7554/eLife.10528.011
Figure supplement 2. Gastrocnemius muscles from wild-type or symptomatic SOD1(G86R) (105 days) mice were cryodissected and probed for total
p73 protein.
DOI: 10.7554/eLife.10528.012
Figure supplement 3. Gastrocnemius muscles from wild-type or symptomatic SOD1(G86R) (105 days) mice were cryodissected and probed for total
p63 protein and nuclei (Hoechst).
DOI: 10.7554/eLife.10528.013
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Figure 5. Expression of p63 and p53-family target genes following sciatic nerve crush, SOD1 expression of induction of stress (A–D) WT and SOD1
(G86R) mice (80 days of age) were anesthetized and the sciatic nerve crushed. Sham-operated contra limbs served as control (Ct). After 7 days,
expression of TA isoforms of Trp63 (A, TAp63), DN isoforms of Trp63 (B, DNp63), Gadd45a (C) and Cdkn1a (D) was assayed by RT-qPCR (n = 6). Values
were normalized to the value of sham-operated WT muscles/animals. Bars represent means (relative induction versus Ct) with standard deviation
(n = 3). *p<0.01 as calculated by a one-way ANOVA test followed by a Tukey post-test. (E) C2C12 myoblasts were transfected with expression vectors
for SOD1 variants (WT or G86R). mRNA from SOD1 transfected cells were analyzed by RT-qPCR for p63 and p63 target gene expression. Bars represent
means (relative induction versus Ct) with standard deviation (n = 3). *p<0.01 as calculated by a one-way ANOVA test followed by a Tukey post-test. (F)
Proteins were extracted from C2C12 myoblasts treated with compounds: FCCP, Tunicamycin (Tun), Etoposide (Eto), menadione (Men). Western blot
analysis revealed TAp63 expression.
DOI: 10.7554/eLife.10528.014
The following figure supplements are available for figure 5:
Figure supplement 1. Regulation of p63 and Mdm2 expression by SOD1 (G86R).
DOI: 10.7554/eLife.10528.015
Figure supplement 2. Functional interaction between members of the p53 family and ER or mitochondrial stress.
DOI: 10.7554/eLife.10528.016
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Mutated SOD1 is sufficient to induce the p63 response in myoblasts
Although it remains a challenge to reproduce in vitro the long-term development of ALS, we tried to
assess the effect of the mutated SOD1 on muscle cells via an overexpression of SOD1(G86R) in the
mouse myoblast cell line C2C12. Several target genes of the p53-family (Bax, Cdkn1a, Gadd45a)
were induced upon overexpression of SOD1(G86R) (Figure 5E). Similarly TAp63 expression was
increased at the mRNA level and the protein level (Figure 5E and Figure 5—figure supplement 1).
In contrast, the mRNA levels as well as the promoter activity of 4N isoforms of P63 were downregu-
lated (Figure 5E, Figure 5—figure supplement 1) (Romano et al., 2006). However, we were not
able to confirm this result on 4Np63 at the protein level. We also tested for a possible cross-regula-
tion of 4Np63 expression by the increased expression of TAp63 observed in ALS. We observed that
TAp63 represses the promoter activity of the 4N isoforms of P63, while it expectedly induces the
Mdm2 promoter (Figure 5—figure supplement 1). These results demonstrated that expression of
SOD1(G86R) was sufficient to trigger a p53-like response similar to our in vivo observations in atro-
phic muscle tissues.
We then investigated whether TAp63 could be induced by different stresses related to the cellu-
lar damages caused by SOD1 mutants. We used pharmacological inductors for oxidative stress
(menadione) (Barber and Shaw, 2010), DNA damage (etoposide) (Aguirre et al., 2005), mitochon-
drial deregulation (FCCP) (Manfredi and Xu, 2005) and ER Stress (tunicamycin) (Hart, 2006;
Nishitoh et al., 2008). Treated cells revealed an increase of TAp63 upon the four stresses
(Figure 5F, Figure 5—figure supplement 2). Mitochondrial and ER stress triggers specific signaling
pathways that involve a complex network of transcription factors such as ATF4, ATF6, XBP1 and
CHOP (Senft and Ronai, 2015). Interestingly, overexpression of ATF4 and ATF6 induces the RNA
level for TAp63 and TAp73 respectively, but not p53 (Figure 5—figure supplement 2). This result
indicated that upregulation of TAp63 expression might be involved in the muscle cell response to
diverse stresses including stresses related to SOD1 mutants.
TAp63 regulates Trim63 (MuRF1) expression, a specific muscle atrophy
effector
As the expression profile of the TA isoforms of Trp63 correlated with the expression of the muscle
atrophy effectors Fbxo32 and Trim63 (Figure 3), we hypothesized that TAp63 could regulate them
directly. Bioinformatic analyses revealed the presence of several putative p63-binding sites in the
promoter of Trim63 (Figure 6A). Therefore, we tested whether TAp63 could regulate Trim63 expres-
sion. Indeed, TAp63 overexpression in C2C12 cells strongly induced Trim63 mRNA levels
(Figure 6B). Fbxo32 expression level was much less affected (data not shown). Note that under this
condition p53 or p73 had less effect on Trim63 expression (Figure 6B). Under the same experimen-
tal conditions, other p63 target genes, Cdkn1a, Pmaip1, Casp1 and Prkaa1 were less induced
(Figure 6C).
To further characterize the regulation of Trim63 by TAp63, we used luciferease reporter con-
structs containing progressive deletions of the Trim63 promoter. We found that p53 family members
induced Trim63 promoter reporters that contained at least the fragment -500 bp to -1000 bp
(Figure 7A and B) (Waddell et al., 2008). Interestingly, that fragment contains potential p63 binding
sites with high probability scores, such as RE1/2 (-660/-690 bp). We then assessed the capacity of
p63 to bind the Trim63 promoter on binding sites that have high probability scores. Chromatin
immunoprecipitation experiments (ChIP) covering RE1/2 and RE4 binding sites showed that TAp63
proteins bound preferentially onto RE1/2 (Figure 7C). Similarly, ChIP experiments indicated that p73
and p53 bound to RE1/2 (Figure 7—figure supplement 1). However, p73 seemed also to bind RE4.
To assess the physiological importance of TAp63 in Trim63 expression we used TAp63-specific
silencing RNA (siRNA). Transfection in C2C12 cells of TAp63siRNA diminished the expression of
TAp63 at the protein and mRNA levels (Figure 7—figure supplement 1). TAp63 silencing or overex-
pression of DNp63 had a partial protective effect on C2C12 (Figure 7—figure supplement 2).
Importantly, silencing of TAp63 reduced Trim63 mRNA levels in both basal state and following stress
induced by FCCP (Figure 7D). SiRNA against p53 also diminished Trim63 RNA level, while siRNA
against p73 had not significant effect (Figure 7—figure supplement 2). The combination of siRNA
against TA isoforms of Trp63, TA isoforms of P73 and P53 diminished further Trim63 RNA level up
to ~50%, but did not abolish it. Taken together, these results indicate a complex regulation of the
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Trim63 promoter, in which the direct binding of p63 and p53 correlates with the modification of
gene expression in C2C12 muscular cells.
Figure 6. Effects of p53-family expression on Trim63 and p53-family target genes. (A) Schematic representation of
the Trim63 promoter indicating the location of putative p53/p63 binding sites. (B, C) C2C12 myoblasts were
transfected (inserted panel: western blot) with various p53-family members (TAp63g , DNp63g , p53, TAp73b,
DNp73b). Total C2C12 RNA was subjected to RT-qPCR after 10 hr or 24 hr of transfection and Trim63 (B) or p63
target (C, Cdkn1a, Pmaip1, Casp1, Prkaa1) expressions are shown relative to control-transfected cells. Bars are
means of fold induction versus the control (Ct) with SD (n=3). *p<0.01 as calculated by a one-way ANOVA test
followed by a Tukey post-test.
DOI: 10.7554/eLife.10528.017
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Discussion
In this study, we developed a comprehensive approach combining biopsies from ALS patients, trans-
genic animal model of ALS and myoblastic cell lines to analyse the expression and the possible func-
tion of P63, a member of the p53 family, in muscle atrophy.
Figure 7. Regulation of Trim63 promoter by p63. (A, B) Trim63 promoter reporter constructs were co-transfected
with pCDNA3 (Ct) or TAp63 into C2C12 cells and luciferase activity was assessed 16 hr later. pGL3 was used as a
negative control. Bars correspond to means with SD (n = 3). *p<0.01 as calculated by a one-way ANOVA test
followed by a Tukey post-test. (C) Chromatin immunoprecipitation assay was performed on the Trim63 promoter
using RT-qPCR on RE1/2 and RE4 (see Figure 6A). Bars correspond to means with SD (n = 3). *p<0.01 as
calculated by a one-way ANOVA test followed by a Tukey post-test. (D) Trim63 mRNA levels were assayed in
C2C12 cells by RT-qPCR after TAp63 silencing by siRNA for 36 hr and after treatment with FCCP for 12 hr. Bars
correspond to means with SD (n=3). *p<0.01 as calculated by a one-way ANOVA test followed by a Tukey post-
test.
DOI: 10.7554/eLife.10528.018
The following figure supplements are available for figure 7:
Figure supplement 1. Regulation of Trim63 by p53 and p73 proteins.
DOI: 10.7554/eLife.10528.019
Figure supplement 2. Impact of p63 on C2C12 cell survival.
DOI: 10.7554/eLife.10528.020
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Regulation of p63 expression during muscular atrophy in ALS patients
and in ALS murine models
Our results demonstrate that there is a complex p53-like response developed by the atrophic muscle
during ALS progression. This assertion is first based on the bioinformatic signalling pathway analyses
of 4 independent microarray experiments performed on muscle biopsies of ALS patients as well as
two different mouse models of ALS. These analyses pointed out a deregulation of p53 as one of the
only three transcription factors deregulated in all four experiments, and common between mouse
and human patient samples. Moreover, detailed expression profile analyses of several p53 target
genes (Cdkn1a, Gadd45a, Pmaip1) or the p53 family member, P63, showed that their expression
correlated significantly with the severity of the pathology in humans. The signalling pathway analyses
were confirmed with groups of individuals independent of those used for the microarrays and by
additional experimental methods. RT-qPCR confirmed the induction of multiple target genes of the
p53 family. In addition, expression analysis of p53 family members indicated that in ALS the P63
gene seems more likely to play a regulatory role as the TAp63 isoforms are strongly upregulated
and localized in the nuclei of the fibers during the ALS pathology (Figures 1, 3, 4, 5, figure supple-
ment 2, 3, 4, 7). Our observation that the deregulation of p63 and p63 target genes occurs in muscle
of ALS patients that have not been selected for a particular genetic alteration indicates that these
deregulations are likely to be a common feature in ALS, independently of whether it is SOD1 that is
mutated or another gene. Additional experiments using other mouse models for TDP43 or FUS
might confirm that. It was previously reported that p63 participates in muscle cell differentiation and
metabolism, and contributes to cardiac muscle development (Cam et al., 2006; Martin et al., 2011;
Rouleau et al., 2011; Su et al., 2012; Osada et al., 1998). Now, by combining biopsies from ALS
patients and an animal model for ALS, the present study provides the first solid evidence that p63
might also participate in muscular atrophy.
Although our results indicate that TAp63 is strongly induced in muscle atrophy during ALS, we
cannot exclude the possible contribution of p53 and p73 proteins due to the fact that their mRNA
expression is upregulated, although to a much weaker extent than TAp63 (Figure 3—figure supple-
ment 4). In addition, we detected p53 and p73 protein expression in muscles tissues. Several studies
support this possibility by showing that p53 and p73 play a role in muscle cell differentiation,
cachexia and survival (Schwarzkopf et al., 2006; Cam et al., 2006, Soddu et al., 1996; Tamir and
Bengal, 1998; Porrello et al., 2000; Weintraub et al., 1991). However, genetic inactivation of p53
does not affect ALS progression, muscle development or muscle regenerative capacity
(Donehower et al., 1992; White et al., 2002; Kuntz et al., 2000; Prudlo et al., 2000). Neverthe-
less, our results suggest that the absence of p53 could be compensated by p63 or even p73. The
slight increased in p53 protein levels observed in protein extracts of muscle from SOD1(G86R) mice
might be caused by the production of ROS that stabilized p53 through post-translational modifica-
tions as previously described in other stresses (Vurusaner et al., 2012). In addition, the slight
increase in p53 RNA level we observed might also contribute.
The causes of p63 regulation during ALS muscle atrophy seemed complex and reflect the
debated etiology of the pathology (Yamanaka et al., 2008; Boille´e et al., 2006; Wong and Martin,
2010; Chen et al., 2013). For instance, we showed that P63 deregulation could have an intercellular
origin represented by the loss of interaction between the muscle and the nerve cells, as provoked in
the nerve crush experiment (Figure 5). Hence, the degeneration of the motor neurons that is charac-
teristic of ALS would be sufficient to explain the increased expression of TAp63 and its target genes
in ALS. However, we also observed that P63 deregulation can have an intrinsic origin resulting from
expression of SOD1(G86R) in muscle cells causing intracellular stresses (Figure 5). Indeed, ALS-asso-
ciated SOD1 mutations have been shown to induce SOD1 protein aggregates and mitochondrial
dysfunction in muscle cells (Pansarasa et al., 2014). Interestingly, we observed that both activation
of a protein aggregate stress response pathway or mitochondrial dysfunction could induce a TAp63
response. This finding is supported by a previous report showing that tp63 is an effector of the ER
stress pathway in zebrafish allowing the regulation of the pro-apoptotic gene bbc3 (puma)
(Pyati et al., 2011).
Protein aggregates, mitochondrial stress and oxidative stress triggered selective complex stress
pathways named ER stress (or UPR, unfolded response) or mitochondrial stressed pathways that uti-
lize several common transcription factors as effectors, such as ATF4, ATF6, CHOP and XBP1
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(Senft and Ronai, 2015; Broadley and Hartl, 2008; Lee, 2015; Michel et al., 2015). Therefore, we
investigated whether these effectors could drive the expression of p53 family protein. We showed
that some of these transcription factors, notably ATF4 and ATF6, were able to induce the RNA levels
of TA isoforms of Trp63 and P73 in C2C12 cells (Figure 5—figure supplement 2). However, bioin-
formatic analyses did not reveal potential canonical binding sites for these transcription factors nei-
ther in promoters of TA isoforms of P63 nor P73, suggesting that the regulation might occur
through indirect mechanisms that remain to be identified.
Function of the p53 response in muscular atrophy during ALS
Based on the literature, the p53 family could mediate different cellular outcomes in muscles and
therefore on muscle pathology. p53/p63/p73 proteins have been linked to cell death, differentiation,
metabolism, ER stress induction and ROS defence, which have all been reported during ALS
(Hart, 2006; Barber and Shaw, 2010; Aguirre et al., 2005; Nishitoh et al., 2008; Manfredi and
Xu, 2005). Our study revealed that the majority of the p53/p63/p73 target genes upregulated dur-
ing ALS in the atrophic muscles are connected to cell death (Gadd45a, Peg3, Perp, Pmaip1, Bax,
Siva, Eda2r, Wig1/Pag608) (Figure 1 and Table 1). Genes connected to other functions, such as ER
stress (chop, bip, xbp1, scotin) or energy metabolism (Tigar, Sesn1, Sesn2, Sco2) seem to be less
consistently regulated, as some are upregulated (Sesn1, Sesn2, Xbp1), while others are downregu-
lated (Sco2, Tigar, Chop, Bip, see Table 1). Therefore, it seems more likely that p53 family members,
notably TAp63, function in ALS is connected to muscular atrophy via control of muscle cell survival
and catabolism. This hypothesis is further supported by three of our results.
First, the p53 family members TAp63, p53 and TAp73 induce the muscle atrophy effector gene
Trim63 (MuRF1), most likely via a direct binding to the Trim63 promoter (Figure 7, Figure 7—figure
supplement 1). Second, overexpression of TAp63 induces cell death in C2C12 myoblasts (Figure 7—
figure supplement 1). Third, overexpression of 4Np63 protects myoblastic cells against stresses
(Figure 7—figure supplement 2). Although these results were obtained in a myoblastic cell line,
they are consistent with numerous other studies describing the ability of p63 to control cell death in
various pathophysiological conditions. To establish the exact pathophysiological importance of
TAp63 upregulation in ALS represent a difficult challenge. Indeed, we already observed that in vitro
the silencing of TAp63 with siRNA does not entirely abolish the expression of Trim63 (Figure 7) and
does not significantly reduce cell death induced by stresses (Figure 7, Figure 7—figure supplement
2). This has several reasons. The first is that the expression of Trim63 involves several transcription
factors, such as FOXO1 and the glucocorticoid receptors that certainly participate in the regulation
of Trim63 during ALS. Indeed, the coordinated silencing of p53, TAp63 and TAp73 did not
completely abolish Trim63 RNA levels (Figure 7—figure supplement 1), supporting the involvement
of other types of transcription factors. The second reason is intrinsic to the p53 family. Indeed, we
already know that p53, p63 and p73 have some redundant functions and target genes. We have also
already established that p53 and p73 are expressed in muscles during the pathology (Figure 4—fig-
ure supplements 1,2) and also bind to the Trim63 promoter (Figure 7—figure supplement 1).
Therefore in absence of TAp63, p53 and/or TAp73 might replace it in some conditions. For example,
we observed an upregulation of TAp73 in C2C12 cells when TAp63 is silenced. This compensatory
mechanism might therefore also explain why TAp63 siRNA do not protect C2C12 cells from death,
in contrast to the expression of the 4Np63 isoform that could inhibit p53, TAp73 and TAp63 func-
tion altogether (Figure 7—figure supplement 2).
ALS patients are currently diagnosed at a stage where denervation and muscular alterations
already are established and, because of the lack of curative treatment, lead to death within 2 to 5
years. The results presented here suggest that p53 family members, via the regulation of selected
target genes such as Eda2r, Peg3 but also, as we show, via Trim63, might contribute to muscle
catabolism in these patients. It remains to be established whether this signalling pathway is uniquely
critical for muscular atrophy during ALS or whether it is common to other muscular atrophies occur-
ring in pathologies such as cachexia, diabetes, and others.
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Materials and methods
SOD1-G86R mice
SOD1(G86R) mice were genotyped as described in (Ripps et al., 1995). For surgery, 80-day-old FVB
mice were anesthetized and both sciatic nerves were exposed at mid thigh level and crushing was
performed (or not – CT) with a forceps during 20 s ~5 mm proximal to the trifurcation. Control ani-
mals used in the experiments were wild-type littermates. Randomization was performed based on
body weight. Time course for animal pathology was performed based on a previous study on dener-
vation and muscle atrophy (von Grabowiecki et al., 2015). Animal experiments were performed fol-
lowing the European guidelines and protocols validated by the local ethical committee.
Cell culture
C2C12 cells were obtained from ATCC (ATCC CRL-1772) and grown in DMEM (Dulbecco’s modified
Eagle’s medium; Life Technology, Carlsbad, CA) with 10% fetal bovine serum (Life Technology) at
37˚C in a humidified atmosphere and 5% CO2. Mycoplasma contamination has been tested nega-
tively using PlasmoTest (Invivogene, San Diego, CA). Differentiation of C2C12 cells was performed
using 2% horse serum at 90% cell confluence.
Quantitative PCR
TRIzol (Invitrogen, Carlsbad, CA) was used to extract RNA. One mg of RNA was used for reverse
transcription (iScript cDNA kit, Bio-Rad, France) and qPCR was carried out (iQ SYBR Green, Bio-Rad)
(Supplementary file 1). Expression levels were normalized using either 18S, TBP or RPB1 as previ-
ously described (Vidimar et al., 2012).
Western blotting
Cells or tissue were lysed with LB (125 mM Tris-HCl pH 6.7, NaCl 150 mM, NP40 0.5%, 10% glyc-
erol). Proteins were denatured and deposited directly (75 mg of proteins) onto a SDS-PAGE gel, or
they were precipitated (2 mg of proteins) with a p63 antibody and G Sepharose beads before sepa-
ration. Western blotting was performed using antibodies raised against p53 (rabbit anti-p53, FL-393,
Santa Cruz Biotechnology, Dallas, TX), p63 (mouse anti-p63, 4A4, Santa Cruz Biotechnology; p63,
Abcam, France) or TAp63 (Biolegend, CA). Secondary antibodies (anti-rabbit, anti-mouse: Sigma,
France) were incubated at 1:1000. Loading was controlled with actin (rabbit anti-b-actin, Sigma,
1:4000) or TBP (anti-TBP 1:1000, Santa Cruz Biotechnology) (Antoine et al., 1996).
Transfection and luciferase assays
Cells were transfected by polyethylenimmine (PEI)-based or JetPrim (Polyplus, Strasbourg, France)
as previously described (Gaiddon et al., 1999). For luciferase assays, cells were seeded in 24-well
plates, and transfected with the indicated expression vectors (200 ng) and reporter constructs (250
ng) (Sohm et al., 1999). Luciferase activity was measured in each well 24 hr later and results were
normalized with a CMV-driven reporter gene (Benosman et al., 2011). The -1584 DNp63 luc and -46
DNp63 luc constructs were previously described (Romano et al., 2006). The Trim63 luc constructs
were previously described (Waddell et al., 2008). SiRNA tranfection was performed using 30 nM of
siRNA and with RNAiMAX protocol as described by the provider (Life Technology). TAp63 siRNA
sequences were covering the sequence: GAA CUU UGU GGA UGA ACC UCC GAA.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed using the standard protocol from the Magna ChIP G kit (Millipore).
C2C12 lysates were sonicated 12 times at 10% power. For each 1 million cells, 1 mg of antibody was
used. p63 was immunoprecipitated with a mouse antibody raised against total p63 (4A4, Santa Cruz
Biotechnology). Mouse-anti-RAB11A was used as negative control (Santa Cruz Biotechnology).
Microarrays analyses
ECL files from microarray experiments (E-MXP-3260; E-GEOD-41414; E-TABM-195; E-GEOD-16361)
were obtained form the Array Express database (EMBL-EBI). Each experiment was first analyzed indi-
vidually using AltAnalysis software (Emig et al., 2010). Deregulated gene were identified based on
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two fold change expression and t-test p-value <0.05. Deregulated genes were then analyzed by
GO-Elite with Prune Ontology term using Z-score (cutoff 1.96, p-value 0.05) and Fisher’s Exact Test
for ORA (2000 permutations) for over-representation in selected biological processes in several
resources: Gene Ontology, MPhenoOntology, Disease Ontology, GOSlim, PathwayCommons,
KEGG, Transcription Factor Targets, miRNA Targets, Domains, BioMarkers, RVista Transcription
Sites, DrugBank, BioGrid.
Immunohistochemistry
Mouse gastrocnemius muscles were sampled, submersed in freezing medium (Tissue-Tek O.C.T
compound, Sakura, Japan) and immediately frozen in a nitrogen-cooled isopentane bath. Muscles
were sliced in transversal axis at 14 mm in a cryostat (Leica CM3050S, Leica, France) and placed on
slides covered with 0.5% gelatine. The samples were then dried for 20 min on a hot plate and fixed
in 4% paraformaldehyde for 10 min . After a 5 min wash with PBS, the samples were permeabilized
with 3% Triton X-100 in PBS for 10 min, washed with TBS, incubated in 100 mM glycine in TBS for
20 min and finally washed again in PBS. The samples were incubated with mouse antibody raised
against p63 (p63 clone 4A4, Santa Cruz Biotechnology) at 1:100 with 0.1% Triton X-100 in PBS (Tri-
ton buffer) overnight at room temperature. They were then washed three times with Triton buffer
for 10 min and incubated with cyanine 3-coupled goat anti-mouse antibody (Jackson ImmunoRe-
search, West Grove, PA) at 1:1000, as well as with 1 mg/ml Hoechst 33,342 (Sigma, France), in Triton
buffer at room temperature for 1 hr. After washing three times with Triton buffer, the slides were
covered with mounting medium (Aqua-Poly/Mount, Polysciences, Warrington, PA) on glass slips and
observed by confocal microscopy (Zeiss, Germany). Antibody specificity was verified with slides
probed with only the secondary antibody.
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